Prime Medicine ($PRME) Stock Forecast: Down 13.7% Today

What is Prime Medicine?

Prime Medicine Inc. (PRME) is a biotechnology company specializing in curative genetic therapies and faced a notable decline in its stock value recently.

Why is Prime Medicine going down?

PRME stock is down 13.7% on Nov 7, 2025 18:02

• PRME disclosed third-quarter financial figures, showcasing a substantial loss and revenue below expectations, resulting in a pessimistic investor outlook.
• Despite appointing a new Chief Business Officer, apprehensions regarding the company's financial standings persisted.
• The market's response might be tied to delays in seeking regulatory approvals for PM577 in Wilson's Disease, impacting confidence in PRME's product lineup and future prospects.
• In summary, the unsatisfactory financial performance coupled with potential setbacks in crucial projects likely contributed to the stock's bearish trend.

PRME Price Chart

PRME Technical Analysis

PRME News

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

-- New preclinical data for PM577 in Wilson's Disease ( WD ) to be presented at AASLD. on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency ( AATD ).

https://www.globenewswire.com/news-release/2025/11/07/3183791/0/en/CORRECTION-Prime-Medicine-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html

Prime Medicine, Inc. ( PRME ) Reports Q3 Loss, Lags Revenue Estimates

Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -14.29% and -75.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2787601/prime-medicine-inc-prme-reports-q3-loss-lags-revenue-estimates

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

CAMBRIDGE, Mass., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Prime Medicine, Inc. ( Nasdaq: PRME ) , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business ...

https://www.globenewswire.com/news-release/2025/11/03/3179239/0/en/Prime-Medicine-Appoints-Matthew-Hawryluk-Ph-D-M-B-A-as-Chief-Business-Officer.html

Trending Today

ZCash ($ZEC) Crypto Forecast: Down 13.5% Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Binance Coin ($BNB) Crypto Forecast: Up 5.4% Today

Prime Medicine Price History

30.06.2025 - PRME Stock was up 5.7%

• PRME's stock trading above the golden cross signifies a bullish signal, indicating the potential for further upward momentum.
• Investors might view this as an opportunity to purchase shares, anticipating favorable developments or strong financial performance from the company.
• The occurrence of the golden cross could be attributed to the optimistic market sentiment surrounding PRME's revolutionary medical solutions or positive developments in the company's product pipeline.
• The uptrend in PRME's stock price reflects investor confidence in the company's future prospects and their willingness to seize potential growth opportunities.

04.07.2025 - PRME Stock was up 6.7%

• Prime Medicine Inc. (PRME) experienced a strong bullish movement today.
• The bullish momentum can be attributed to the successful closing of a public offering and the full exercise of the underwriters' option to purchase additional shares, indicating strong investor interest and confidence in the company's future prospects.
• The company's focus on delivering a new class of differentiated one-time curative genetic therapies seems to have resonated well with investors, leading to increased buying activity.
• The stock trading above the golden cross further reinforces positive sentiment and may attract more investors looking for potential buying opportunities in PRME.

15.08.2025 - PRME Stock was down 5.7%

• Cathie Wood's Ark Invest reducing its holdings in a popular AI stock might have triggered worries among investors about the sector's growth outlook.
• A notable transaction involving Tempus AI Inc could have prompted uncertainties about the company's future results, potentially causing a decline in related AI stocks like PRME.
• Investors' response to these developments may have led to the selling of PRME shares, influencing the stock's bearish performance today.

07.07.2025 - PRME Stock was down 8.0%

• PRME reported a Q2 loss and missed revenue estimates, signaling potential financial challenges ahead.
• The announcement of the closing of a public offering and the full exercise of underwriters' option to purchase additional shares might have led to dilution concerns among investors, contributing to the bearish movement.
• The market may be reacting negatively to the company's financial performance and the implications of the recent public offering on its future earnings potential.
• Investors could be cautious about PRME's ability to execute its strategic plans effectively in the competitive biotechnology industry, leading to a decline in the stock price.

16.06.2025 - PRME Stock was down 7.7%

• The additional funding of up to $24 million from the Cystic Fibrosis Foundation is positive news for PRME, indicating confidence in their Prime Editing treatments for Cystic Fibrosis.
• However, the market may have reacted bearishly due to concerns about potential dilution from the new funding, leading to profit-taking by investors.
• Investors might also be cautious about the timeline for the development of Prime Editors for Cystic Fibrosis, leading to a short-term bearish sentiment in the stock.

02.06.2025 - PRME Stock was up 32.4%

• PRME experienced a strong bullish movement today.
• The positive momentum in PRME's stock could be attributed to the overall bullish sentiment in the tech sector.
• Hut 8 Corp's announcement of a significant infrastructure win in Ontario may have boosted investor confidence in the renewable energy sector, positively impacting PRME's stock price.
• Investors may be viewing PRME as a potential beneficiary of the growing interest in renewable energy solutions, driving up the stock price.

22.04.2025 - PRME Stock was up 9.7%

• PRME stock surged after the announcement of promising clinical data for PM359, indicating a swift restoration of DHR positivity in Chronic Granulomatous Disease patients.
• The Phase 1/2 trial results for PM359, showcasing the effectiveness of Prime Editing technology, bolstered investor confidence and uplifted the stock price.
• By focusing on genetic liver diseases and cystic fibrosis, along with favorable clinical trial outcomes, Prime Medicine's strategic realignment contributed to the optimistic sentiment surrounding the company's stock.
• The market's positive response reflects a growing belief in Prime Medicine's innovative gene editing approach and its potential to address unmet medical needs across various genetic disorders.

07.10.2025 - PRME Stock was down 13.7%

• PRME disclosed third-quarter financial figures, showcasing a substantial loss and revenue below expectations, resulting in a pessimistic investor outlook.
• Despite appointing a new Chief Business Officer, apprehensions regarding the company's financial standings persisted.
• The market's response might be tied to delays in seeking regulatory approvals for PM577 in Wilson's Disease, impacting confidence in PRME's product lineup and future prospects.
• In summary, the unsatisfactory financial performance coupled with potential setbacks in crucial projects likely contributed to the stock's bearish trend.

07.10.2025 - PRME Stock was down 10.5%

• PRME reported a Q3 loss and missed revenue estimates by a significant margin, leading to investor concerns about the company's financial performance.
• The appointment of a new Chief Business Officer may have initially been seen as a positive move, but the market reaction suggests that investors are more focused on the company's financial health.
• The disappointing financial results indicate potential challenges in the company's operations or market acceptance of its therapies, contributing to the bearish movement in PRME's stock price.
• Investors may be cautious about PRME's future prospects until there is more clarity on its ability to improve financial performance and deliver on its promise of innovative genetic therapies.

29.04.2025 - PRME Stock was up 5.3%

• Prime Medicine's participation in upcoming investor conferences may have sparked investor interest and confidence in the company's future prospects.
• The overall positive sentiment in the biotech sector, highlighted by recent industry developments, could have positively influenced PRME's stock price.
• Investors might be optimistic about Prime Medicine's innovative approach to genetic therapies, leading to increased buying activity and driving the stock higher.

31.06.2025 - PRME Stock was down 6.3%

• The pricing of the underwritten public offering of 38,000,000 shares might have led to increased selling pressure on the stock, causing a bearish movement.
• The anticipation of the public offering could have created uncertainty among investors, leading to a negative sentiment towards the stock.
• The mention of a golden cross event in recent commentary might have initially sparked some interest, but the actual pricing of the public offering might have outweighed any positive sentiment, resulting in the bearish movement.
• Investors may have perceived the public offering as dilutive to the existing shares, impacting the stock price negatively.

03.10.2025 - PRME Stock was down 5.9%

• The recent hiring of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer may have fallen short of investor expectations, resulting in a lack of confidence in the company's strategic course.
• Concerns may arise among investors regarding how this appointment could influence Prime Medicine's current projects and future growth opportunities.
• The market's response suggests doubt or hesitation about the company's ability to fulfill its commitment to innovative genetic treatments, generating a pessimistic outlook among investors.